Acute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia
Conditions
Keywords
Refractory acute myeloid leukemia, Relapsed acute myeloid leukemia
Brief summary
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.
Detailed description
* Phase I * The maximum tolerated dose (MTD) will be determined in the phase I section of the trial. * Patients who fulfill eligibility criteria will be entered into the trial to GO-203-2c. * After the screening procedures confirm participation in the research study. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have acute myeloid leukemia (AML) not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated. * A subsequent dose escalation will evaluate the combination of GO-203-2c and decitabine. * Phase II * The primary goal is to determine if the combination of the two drugs results in clinical response
Interventions
DRUGGO-203-2c
DRUGGO-203-2c + Decitabine
Sponsors
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* To be considered eligible for enrollment into this study, all of the following inclusion criteria must be met during the screening period: * Documented AML by peripheral blood and bone marrow analyses meeting WHO criteria, excluding patients with acute promyelocytic leukemia (APL) * Patients with AML refractory to primary induction chemotherapy, relapsed disease, or age ≥ 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician * Age ≥ 18 years * Karnofsky performance status ≥ 50% or ECOG performance status 0-2 * Life expectancy ≥ 6 weeks * Able to understand the investigational nature of this study and to provide written consent to participate in it * Signed written IRB-approved Informed Consent document * Adequate hepatic and renal function: * serum bilirubin ≤ 1.5 X institutional ULN OR serum direct bilirubin ≤ 2 X institutional ULN * serum ALT and AST ≤ 2.5 X institutional ULN * serum alkaline phosphatase \< 5 X institutional ULN * serum creatinine ≤ 2.0 mg/dL * corrected calcium level ≥ institutional LLN * Negative pregnancy test in women of child-bearing potential * Women and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)
Exclusion criteria
* A patient will be considered not eligible for enrollment into this study if any of the following criteria are met during the screening period: * Evidence of leukemic meningitis or other CNS involvement by leukemia * Uncontrolled or poorly controlled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg) Note: an isolated reading that is not sustained will be permitted. * Evidence of NYHA Class III or IV cardiac disease, or presence of unstable life-threatening arrhythmia, or history of myocardial infarction during the past 6 months * Active bacterial, fungal, or viral infection requiring systemic treatment * Known infection with HIV * History or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery * Exposure to any other investigational agent at any time within 4 weeks before the first dose of study treatment * Exposure to any other anti-leukemic therapy (except hydroxyurea, see Section 5.5.1) within 2 weeks before the first dose of study treatment * Pregnant or lactating female * Unwilling or unable to comply with the requirements of the study protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose of GO-203-2c | 28 days | Phase I: Maximum Tolerated Dose of GO-203-2c |
| Maximum Tolerated Dose of GO-203-2c in combination with decitabine | 28 days | Phase 1: Maximum Tolerated Dose of GO-203-2c in combination with decitabine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability | 2 years | Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
| Determine if therapy results in at least 20% of patients achieving a clinical response | 2 years | To determine if therapy GO-203-2c in combination with decitabine results in at least 20% of patients achieving a clinical response (blast response, minor response, partial response, or complete response). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDavid Avigan, MD
Beth Israel Deaconess Medical Center
Outcome results
None listed